Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022.
Nathaniel M LewisNancy MurrayKatherine AdamsDiya SurieManjusha GaglaniAdit A GindeTresa McNealShekhar GhamandeDavid J DouinH Keipp TalbotJonathan D CaseyNicholas M MohrAnne ZepeskiNathan I ShapiroKevin W GibbsD Clark FilesDavid N HagerHarith AliMatthew E PrekkerAnne E FroschMatthew C ExlineMichelle N GongAmira MohamedNicholas J JohnsonVasisht SrinivasanJay S SteingrubIthan D PeltanSamuel M BrownEmily T MartinArnold S MontoAdam S LauringAkram KhanCatherine L HoughLaurence W BusseWilliam BenderAbhijit DuggalJennifer G WilsonAlexandra June GordonNida QadirSteven Y ChangChristopher MallowCarolina RivasHilary M BabcockJennie H KwonJames D ChappellNatasha HalasaCarlos G GrijalvaTodd W RiceWilliam B StubblefieldAdrienne BaughmanChristopher J LindsellKimberly W HartJillian P RhoadsMeredith L McMorrowMark W TenfordeWesley H SelfManish M Patelnull nullPublished in: Open forum infectious diseases (2022)
Vaccine booster doses increased protection against COVID-19 hospitalization compared with a primary series. Comparing rVE measures across studies can lead to flawed interpretations of the added value of a new vaccination regimen, whereas difference in aVE, when available, may be a more useful metric.